Kedrion: at ESID 2026, experts call for earlier diagnosis and greater awareness as Secondary Immunodeficiencies continue to rise

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Kedrion

More Like This

PR Newswire associated0

Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions innovation and patient care

PR Newswire associated0

Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

PR Newswire associated0

European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's plasma-derived treatment for Congenital Aceruloplasminemia, a rare genetic disorder of iron metabolism

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023

SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026